Biotheryx Announces Research Collaboration and License Agreement with Incyte for Discovery of Targeted Protein Degraders for Novel Oncology Targets April 12, 2023
Scorpion Therapeutics and Pierre Fabre to Co-Develop and Commercialize STX-721 and STX-241 for Patients with EGFRm NSCLC April 12, 2023
Genenta Announces Extension of License Agreement with Ospedale San Raffaele to All Solid Tumor Indications April 12, 2023
First Subject Dosed in Ph 1 KisMET-01 Clinical Trial of MYTX-011 for the Treatment of NSCLC April 12, 2023
Clinical Data of KEYNOTE-695 Trial of TAVO™-EP + KEYTRUDA in Patients with Advanced Melanoma Refractory to anti-PD-1 Treatment announced April 12, 2023
Lynparza and Imfinzi combination improved PFS in newly diagnosed patients with advanced ovarian cancer without tumour BRCA mutations in DUO-O Ph 3 trial April 12, 2023
FAILED TRIALS: Ph 3 LEAP-003 trial of KEYTRUDA + LENVIMA in 1L metastatic melanoma to be discontinued; combo’s Ph 3 LEAP-017 trial in 1L pMMR mCRC didn’t meet primary endpoint of OS improvement April 12, 2023
IMBRUVICA’s U.S. Accelerated Approvals for Mantle Cell Lymphoma and Marginal Zone Lymphoma Indications to be voluntarily withdrawn April 12, 2023
mRNA-4157/V940 (mRNA Cancer Vaccine + KEYTRUDA) Receives PRIME Scheme Designation from the EMA for Adjuvant Treatment of Patients with High-Risk Stage III/IV Melanoma Following Complete Resection April 12, 2023
FDA Accepts Supplemental NDAs for BRAFTOVI + MEKTOVI in patients with mNSCLC with a BRAF V600E mutation April 12, 2023
FDA Approves KEYTRUDA + Padcev combination for 1L Treatment of Certain Patients With Locally Advanced or Metastatic Urothelial Cancer April 12, 2023
